South Korean pharmaceutical company Yuhan (KRX:000100) secured a 78.6 billion won supply contract for an active pharmaceutical ingredient (API) from an undisclosed global pharmaceutical firm, according to a Wednesday filing with the Korea Exchange.
The contract is valid from Sept. 15, 2026, to July 31, 2028.
Shares of Yuhan fell nearly 3% at market close.